Navigation Links
Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
Date:10/2/2007

ans to advance the development of Celacade(TM), plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the avail
'/>"/>
SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... SAN DIEGO, Feb. 3 Gen-Probe Incorporated (Nasdaq: ... has joined the Company as senior vice president, research ... expertise and leadership to our already strong senior management ... officer. "We believe Eric will play an integral ...
... Primary and Key Secondary Endpoints -- CAPACITY 1 Misses ... Submit NDA and MAA -BRISBANE, Calif., Feb. 3 ... results from the two Phase 3 CAPACITY studies evaluating ... The primary endpoint of change in percent predicted Forced ...
... is like none other. To mark the observance, African ... promote science education, achievement motivation and positive psychological development among ... ... Washington, DC (PRWEB) February 3, 2009 -- African Ancestry, Inc., ...
Cached Biology Technology:Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development 2InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 2InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 3InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 4InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 5InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 6InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 8InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 9InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 10InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 11African Ancestry, Educators, Identity Experts Launch DNA Education Project during Historic Black History Month; 7th Graders Score High on Ultimate Self Test 2African Ancestry, Educators, Identity Experts Launch DNA Education Project during Historic Black History Month; 7th Graders Score High on Ultimate Self Test 3
(Date:7/9/2014)... Calif. Jason Stajich , an associate professor ... University of California, Riverside, has been awarded the 2014 ... America, a scientific society dedicated to advancing the science ... kinds including mushrooms, molds, truffles, yeasts, lichens, plant pathogens, ... and each year recognizes an outstanding early-career mycologist. Stajich ...
(Date:7/9/2014)... species, selection for traits that are attractive to the ... opportunities to mate, the tail of male peacocks being ... California, Riverside have now found that sexual selection and ... linked. Describing the life histories of more than 150 ... found that species with placentas tend to have males ...
(Date:7/9/2014)... studying critically ill children with traumatic injuries have ... are likely to develop a hospital-acquired infection. The ... and published online in June in the journal ... efforts that could lead to the clinical implementation ... prevent or reverse immune system damage following critical ...
Breaking Biology News(10 mins):UC Riverside plant pathologist receives national recognition 2Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... tree ring-based reconstruction of an extinct polar forest,s ... impact of Lake St. Martin bolide on groundwater ... boundary; radar images of volcanic and impact deposits ... into the atmosphere; use of charred plants in ...
... -- The National Academy of Sciences (NAS) will honor ... the areas of biology, chemistry, solar physics, ecology, mathematics, ... awards and recipients for 2008 are: ARCTOWSKI MEDAL ... well as a gift of $60,000 to an institution ...
... Climate Change for the Baltic Sea Basin (BACC), the book ... and possible future climate change in the region, which extends ... mid-Europe. One of the key findings is that air temperatures ... five degrees Celsius from now to 2100. More than 80 ...
Cached Biology News:February Geology and GSA Today media highlights 2February Geology and GSA Today media highlights 3February Geology and GSA Today media highlights 4February Geology and GSA Today media highlights 5February Geology and GSA Today media highlights 6February Geology and GSA Today media highlights 7February Geology and GSA Today media highlights 8February Geology and GSA Today media highlights 9February Geology and GSA Today media highlights 10Academy honors 13 for major contributions to science 2Academy honors 13 for major contributions to science 3Academy honors 13 for major contributions to science 4Academy honors 13 for major contributions to science 5Climate change in the Baltic Sea basin -- past, present and future 2Climate change in the Baltic Sea basin -- past, present and future 3
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: